{"paper_id":"eb73052f-fa01-427c-8a17-f9f4976aea0e","body_text":"Abstract\nPurpose\nWe examined the association between use of low-dose aspirin and non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) and endometrial cancer risk in a nationwide case–control study.\nMethods\nCases were all women in Denmark diagnosed with endometrial cancer during 2000–2009. Age-matched female controls were randomly selected by risk-set sampling. Information on NSAID use was collected from the Prescription Registry and classified according to duration and intensity. Conditional logistic regression was used to calculate odds ratios (ORs) and 95 % confidence intervals (CIs), adjusting for potential confounders. Analyses were stratified by endometrial cancer type, and potential effect modification by parity, obesity, and hormone replacement therapy (HRT) use was investigated.\nResults\nWe identified 5,382 endometrial cancer cases and 72,127 controls. Endometrial cancer was not associated with use of low-dose aspirin (OR 0.97, 95 % CI 0.89–1.05) or non-aspirin NSAIDs (OR 0.96, 95 % CI 0.91–1.02) compared with nonuse. The ORs did not vary with increasing duration or intensity of NSAID use or with type of endometrial cancer. Interaction analyses showed reduced endometrial cancer risk associated with low-dose aspirin use among nulliparous women (OR 0.82, 95 % CI 0.70–0.95) and with non-aspirin NSAID use among women having used HRT (OR 0.90, 95 % CI 0.82–0.99).\nConclusions\nWe found no association between use of NSAIDs and endometrial cancer risk overall, although there were some indications of risk reductions associated with low-dose aspirin use among nulliparous women and with non-aspirin NSAID use among women having used HRT.\nSimilar content being viewed by others\nReferences\nSorosky JI (2012) Endometrial cancer. Obstet Gynecol 120:383–397\nAkhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P (2001) Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci 943:296–315\nSiiteri PK (1978) Steroid hormones and endometrial cancer. Cancer Res 38:4360–4366\nModugno F, Ness RB, Chen C, Weiss NS (2005) Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol Biomarkers Prev 14:2840–2847\nWallace AE, Gibson DA, Saunders PT, Jabbour HN (2010) Inflammatory events in endometrial adenocarcinoma. J Endocrinol 206:141–157\nNeill AS, Nagle CM, Protani MM, Obermair A, Spurdle AB, Webb PM (2013) Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. Int J Cancer 132:1146–1155\nUlrich CM, Bigler J, Potter JD (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6:130–140\nThun MJ, Jacobs EJ, Patrono C (2012) The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9:259–267\nOhno S, Ohno Y, Suzuki N et al (2005) Multiple roles of cyclooxygenase-2 in endometrial cancer. Anticancer Res 25:3679–3687\nKilic G, Gurates B, Garon J et al (2005) Expression of cyclooxygenase-2 in endometrial adenocarcinoma. Eur J Gynaecol Oncol 26:271–274\nGao J, Niwa K, Sun W et al (2004) Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells. Cancer Sci 95:901–907\nOzalp SS, Eren CY, Bostancioglu RB, Koparal AT (2012) Induction of apoptosis and inhibition of cell proliferation by the cyclooxgenase enzyme blocker nimesulide in the Ishikawa endometrial cancer cell line. Eur J Obstet Gynecol Reprod Biol 164:79–84\nFriis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH (2003) A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 88:684–688\nSorensen HT, Friis S, Norgard B et al (2003) Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 88:1687–1692\nDanforth KN, Gierach GL, Brinton LA et al (2009) Nonsteroidal anti-inflammatory drug use and endometrial cancer risk in the NIH-AARP Diet and Health Study. Cancer Prev Res 2:466–472\nPrizment AE, Folsom AR, Anderson KE (2010) Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women’s Health Study. Cancer Epidemiol Biomarkers Prev 19:435–442\nSchreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138–146\nBrasky TM, Moysich KB, Cohn DE, White E (2013) Non-steroidal anti-inflammatory drugs and endometrial cancer risk in the VITamins And Lifestyle (VITAL) cohort. Gynecol Oncol 128:113–119\nPhipps AI, Anderson GL, Cochrane BB et al (2012) Migraine history, nonsteroidal anti-inflammatory drug use, and risk of postmenopausal endometrial cancer. Horm Cancer 3:240–248\nSetiawan VW, Matsuno RK, Lurie G et al (2012) Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev 21:1441–1449\nBlenstrup LT, Knudsen LB (2011) Danish registers on aspects of reproduction. Scand J Public Health 39:79–82\nGjerstorff ML (2011) The Danish Cancer Registry. Scand J Public Health 39:42–45\nJensen VM, Rasmussen AW (2011) Danish education registers. Scand J Public Health 39:91–94\nKildemoes HW, Sorensen HT, Hallas J (2011) The Danish National Prescription Registry. Scand J Public Health 39:38–41\nLynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public Health 39:30–33\nPedersen CB (2011) The Danish Civil Registration System. Scand J Public Health 39:22–25\nRothman K, Greenland S, Lash TL, Rothman K, Greenland S, Lash TL (2008) Case-control studies. Modern epidemiology, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 111–127\nSchmidt M, Hallas J, Friis S (2014) Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in Denmark: trends in utilization 1999–2012. Clin Epidemiol 6:155–168\nATC Classification Index with DDDs. World Health Organization Collaborating Centre for Drug Statistics Methodology.http://www.whocc.no/atc_ddd_index/. Accessed 16 Oct 2014\nRay WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915–920\nR Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.http://www.R-project.org/. Accessed 2 Nov 2014\nBrasky TM, Liu J, White E et al (2014) Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women’s Health Initiative. Int J Cancer 135:1869–1883\nFortuny J, Sima C, Bayuga S et al (2009) Risk of endometrial cancer in relation to medical conditions and medication use. Cancer Epidemiol Biomarkers Prev 18:1448–1456\nBodelon C, Doherty JA, Chen C, Rossing MA, Weiss NS (2009) Use of nonsteroidal antiinflammatory drugs and risk of endometrial cancer. Am J Epidemiol 170:1512–1517\nViswanathan AN, Feskanich D, Schernhammer ES, Hankinson SE (2008) Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res 68:2507–2513\nMoysich KB, Baker JA, Rodabaugh KJ, Villella JA (2005) Regular analgesic use and risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 14:2923–2928\nBosetti C, Bravi F, Talamini R, Montella M, Negri E, La VC (2010) Aspirin and risk of endometrial cancer: a case-control study from Italy. Eur J Cancer Prev 19:401–403\nCook NR, Lee IM, Zhang SM (2013) Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 159:77–85\nCook NR, Lee IM, Gaziano JM et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294:47–55\nCuzick J, Thorat MA, Bosetti C et al (2014) Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. doi:10.1093/annonc/mdu225\nRothwell PM, Price JF, Fowkes FG (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379:1602–1612\nPurdie DM, Green AC (2001) Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol 15:341–354\nHarvey AE, Lashinger LM, Hursting SD (2011) The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci 1229:45–52\nYood MU, Campbell UB, Rothman KJ et al (2007) Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf 16:961–968\nAcknowledgments\nNB was funded by a scholarship from the Lundbeck Foundation. The funding source had no role in the design, analysis, and interpretation of the results.\nConflict of interest\nThe authors declare that they have no conflict of interest.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nElectronic supplementary material\nBelow is the link to the electronic supplementary material.\nRights and permissions\nAbout this article\nCite this article\nBrøns, N., Baandrup, L., Dehlendorff, C. et al. Use of nonsteroidal anti-inflammatory drugs and risk of endometrial cancer: a nationwide case–control study. Cancer Causes Control 26, 973–981 (2015). https://doi.org/10.1007/s10552-015-0578-4\nReceived:\nAccepted:\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s10552-015-0578-4","source_license":"CC0","license_restricted":false}